Comparative Pharmacology
Head-to-head clinical analysis: FLUDEOXYGLUCOSE F18 versus SODIUM PERTECHNETATE TC 99M.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUDEOXYGLUCOSE F18 versus SODIUM PERTECHNETATE TC 99M.
FLUDEOXYGLUCOSE F18 vs SODIUM PERTECHNETATE TC 99M
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fludeoxyglucose F18 is a glucose analog that is taken up by cells via glucose transporters (GLUT), particularly GLUT-1. It is phosphorylated to FDG-6-phosphate by hexokinase, which cannot be further metabolized, leading to intracellular accumulation proportional to glucose metabolism. It emits positrons detected by PET imaging.
Sodium pertechnetate Tc-99m is a radiopharmaceutical that emits gamma rays (140 keV). The pertechnetate anion (TcO4−) is taken up by the thyroid gland via the sodium-iodide symporter (NIS) and also distributes in salivary glands, gastric mucosa, and choroid plexus. It acts as a diagnostic imaging agent by localizing in tissues via active transport or diffusion, allowing external detection with gamma cameras.
5-10 mCi (185-370 MBq) intravenous injection, single dose for PET imaging.
370-1110 MBq (10-30 mCi) intravenously as a single dose for brain imaging; 370-740 MBq (10-20 mCi) intravenously for thyroid imaging; 185-370 MBq (5-10 mCi) intravenously for salivary gland imaging.
None Documented
None Documented
Terminal elimination half-life is approximately 110 minutes (range 100–120 minutes). This reflects clearance of unmetabolized FDG from plasma and is clinically relevant for imaging timing, as optimal image acquisition occurs 30–60 minutes post-injection to allow for target-to-background ratio maximization.
Terminal elimination half-life: approximately 6 hours. Clinical context: Allows for imaging up to several hours post-injection; clearance is delayed in renal impairment.
Primarily renal; approximately 90% of injected activity is excreted unchanged in urine within the first 2 hours post-injection. Less than 5% is eliminated via feces.
Renal: approximately 30-50% of the injected dose is excreted in urine within 24 hours. The remainder is eliminated via the hepatobiliary system into feces.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical